NeraCare Announces Publication of Abstract on Clinical Validation of a Prognostic 7-Biomarker Assay for Prediction of Relapse in Patients with Early-Stage Cutaneous Melanoma at the 2024 Am...
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: Yahoo! F
Patients with stage IB/IIA melanoma identified as high-risk had a relapse rate comparable to later-stage patients for whom adjuvant therapy is already approved The prognostic assay may be useful in selecting early-stage melanoma patients for adjuvant trials Assay is being transferred to the Akoya Biosciences' PhenoImager® HT multiplex platform to enable automation and tissue preservation FRANKFURT, Germany, May 23, 2024 BUSINESS WIRE NeraCare , a leading developer of laboratory tests for personalized survival prediction of melanoma patients, today announced publication of an abstract describing the clinical validation of a prognostic seven biomarker immunohistochemistry (7-IHC; Immunoprint) risk categorization assay that stratifies patients with early-stage (IB/IIA) cutaneous melanoma into high-risk or low-risk groups for recurrence and melanoma-specific survival, on the American Society of Clinical Oncology (ASCO) website Results of the Melarisk-001 study demonstrated that u
Show less
Read more
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.MarketBeat
- Akoya Biosciences Second Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its price target lowered by analysts at Craig Hallum from $7.50 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Akoya Biosciences, Inc. (NASDAQ: AKYA) was downgraded by analysts at BTIG Research from a "buy" rating to a "neutral" rating.MarketBeat
AKYA
Earnings
- 8/5/24 - Miss
AKYA
Sec Filings
- 9/3/24 - Form 4
- 9/3/24 - Form 3
- 8/28/24 - Form SC
- AKYA's page on the SEC website